Earnings per share (EPS) of $0.54 exceeded the $0.50 forecast. Despite matching the expected target of $1.6 billion, revenue for the quarter declined 4.4% from the prior year's $1.68 billion.

Revenue: US$43.8m (up 40% from FY 2023). Net income: US$25.9m (up 78% from FY 2023). Profit margin: 59% (up from 46% in FY 2023). The increase in margin was driven by higher revenue. Looking ahead ...

Sunnova's Q4 2024 EPS missed analyst expectations by a wide ... the company's net contracted customer value per share decreased by 4%, and it faced a challenging capital markets environment ...

Revenue: RM378.9m (up 28% from FY 2023). Net income: RM21.9m (up 55% from FY 2023). Profit margin: 5.8% (up from 4.8% in FY 2023). The increase in margin was driven by higher revenue. We don't want to ...

According to the latest whisper across the rumor mill, the fabled return of the mid-engine Toyota MR2 and feisty Celica 4WD is just around the corner, along with a Lexus surprise – and the peeps ...

Even with so few options on our hands, if you'd ask me to pick my favorite from this small and select bunch, then the Polaris Slingshot is certainly what I would go for. The nameplate was ...

You can not sell your investments in this fund for 3 years from the purchase date. Long term capital gain tax will be applicable when you sell your investments after 3 years. Current tax rate is ...

Reports Q4 revenue $632.85M, consensus $667.4M. “As we turn the page on the first year operating as a combined company following the acquisition of Omni, I want to express my gratitude to our ...

NRG reported Q4 revenue of $6.858B, missing estimates, while adjusted EPS of $1.52 beat the $1.29 consensus ... Adjusted EBITDA rose 4.7% YoY to $902 million, and the margin expanded 43 bps ...

National Vision exceeded both EPS and revenue forecasts for Q4 2024. The stock price jumped significantly in premarket trading, reflecting strong investor confidence. The company provided a ...

Reports Q4 revenue $47.54M, consensus $45.29M. “2024 was a terrific year for Geron (GERN) and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly ...

Adjusted EPS of $2.52, beating estimates of $2.45 and up 6.3% year over year. Quarterly revenue of $1.53 billion came in slightly above the estimate and rose 4.2% year over year. Average Daily ...